IDH突变弥漫性低级别胶质瘤临床管理变化:15年间的治疗模式
在斯堪的纳维亚人群基础上,纳入2007年1月至2021年6月手术的202例≥18岁原发性IDH突变弥漫性低级别胶质瘤(2级和3级)患者,按2007-2011、2012-2016、2017-2021三个亚组比较肿瘤特征、治疗和术后结局。结果显示后期完全切除比例增加(6.1%、15.7%、26.1%,p=0.016)而术后神经功能缺损无显著增加(14.8%、23.6%、23.2%,p=0.379);辅助肿瘤治疗模式显著变化,质子放疗逐渐取代光子放疗。
要点
- 后期完全切除比例增加(6.1%、15.7%、26.1%,p=0.016),术后神经功能缺损未显著增加(p=0.379)。
- 早期单纯放疗减少(32.8%、7%、2.9%,p<0.001),序贯放化疗增加(0%、18%、49.3%,p<0.001)。
- 质子放疗在后期逐渐取代光子放疗(p<0.001)。
核心结论
- 后期完全切除更常实施,且手术并发症无明显增加;早期辅助肿瘤治疗后期更多转向化疗和联合放化疗;质子放疗取代光子放疗成为首选放疗方式。
研究设计与样本
- 在斯堪的纳维亚人群基础上识别2007年1月至2021年6月手术的≥18岁原发性IDH突变弥漫性低级别胶质瘤2级和3级患者,按2007-2011、2012-2016、2017-2021三个亚组比较肿瘤和疾病特征、治疗及术后结局。
主要发现
- 共识别202例患者(2007-2011年n=61;2012-2016年n=72;2017-2021年n=69),其中193例接受切除术,切除术比例随时间无变化。
- 完全切除比例在三个亚组分别为6.1%、15.7%、26.1%(p=0.016)。
- 42例患者术后出现任何神经功能缺损,三个亚组分别为14.8%、23.6%、23.2%(p=0.379),多为轻微且短暂。
- 早期单纯放疗比例在三个亚组分别为32.8%、7%、2.9%(p<0.001);同步放化疗分别为23%、37.5%、17.4%(p=0.022);序贯放化疗分别为0%、18%、49.3%(p<0.001);无辅助治疗分别为42.6%、23.6%、18.8%(p=0.009)。
- 后期亚组中接受质子放疗相比光子放疗的患者越来越多(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isocitrate dehydrogenase (IDH) mutated diffuse lower-grade gliomas (dLGG) are infiltrating brain tumors and increasing evidence is in favor of early multimodal treatment. In a Scandinavian population-based setting, we wanted to study treatment patterns over the last 15 years, focusing on the short-term postoperative course to better understand the potential negative consequences of treatment. METHODS: Patients ≥ 18 years with primary IDH-mutated dLGG grade 2 and 3, operated between January 2007-June 2021 were identified. Patients were divided into subgroups (2007-2011, 2012-2016, and 2017-2021) and comparisons regarding tumor- and disease characteristics, treatment, and postoperative outcome were performed. RESULTS: We identified 202 patients (n = 61, 2007-2011; n = 72, 2012-2016; n = 69, 2017-2021), where of 193 underwent resection without change in proportion of resections over time. More patients underwent complete resections in recent times (6.1%; 15.7%; 26.1%, respectively; p = 0.016). Forty-two patients had any neurological deficit postoperatively (14.8%; 23.6%; 23.2%; p = 0.379), mostly minor and transient. Differences in oncological therapy were seen between the investigated subgroups. Early radiotherapy alone (32.8%; 7%; 2.9%; p < 0.001), concomitant chemoradiotherapy (23%; 37.5%; 17.4%; p = 0.022), sequential chemoradiotherapy (0%; 18%; 49.3%; p < 0.001), and no adjuvant treatment (42.6%; 23.6%; 18.8%; p = 0.009) shifted during the studied period. Increasingly more patients received proton radiotherapy compared to photon radiotherapy during the later time periods (p < 0.001). CONCLUSION: Complete resections were performed more often in later time periods without an apparent increase in surgical morbidity. Early adjuvant oncological treatment shifted towards providing chemotherapy and combined chemoradiotherapy more often in later time periods. Protons replaced photons as the radiation modality of choice.
引用
- Svenjeby C, Carstam L, Werlenius K, et al. Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period. J Neurooncol. 2022. PMID: 36434487. doi:10.1007/s11060-022-04136-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。